Literature DB >> 2407491

Vascular effects of ACE inhibition by perindopril.

J B Michel1, B I Levy.   

Abstract

Hypertension and ageing are associated with decreased arterial compliance, increased thickening of the arterial wall, hypertrophy of arterial smooth muscle cells and an increase in the collagen content of the arterial wall. Increased blood pressure has been implicated as a causative factor in such adaptive vascular alterations, however, other factors, including angiotensin II and epidermal growth factor also induce one or more of these adaptations. Long term use of the angiotensin-converting enzyme (ACE) inhibitor perindopril 1 mg/kg has been shown to reduce blood pressure in spontaneous and renovascular hypertensive rats. Associated with this antihypertensive effect, perindopril completely reversed aortic medial thickening, increased arterial compliance (by 42%) and decreased aortic smooth muscle cell nucleus density (by 13%), but had no significant effect on the elastin: collagen ratio of the arterial wall. In contrast, in spontaneously hypertensive animals, perindopril partially reversed aortic medial thickening and had no significant effect on arterial compliance, despite significantly increasing the arterial wall elastin: collagen ratio in this experimental group. The effect of ACE inhibition appears to directly reflect the role of angiotensin II in the pathogenesis of different hypertensive states.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2407491     DOI: 10.2165/00003495-199000391-00007

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  20 in total

1.  The fourth Volhard lecture: cardiovascular structural adaptation; its role in the initiation and maintenance of primary hypertension.

Authors:  B Folkow
Journal:  Clin Sci Mol Med Suppl       Date:  1978-12

2.  Effects of hypertension on the static mechanical properties and chemical composition of the rat aorta.

Authors:  C L Berry; S E Greenwald
Journal:  Cardiovasc Res       Date:  1976-07       Impact factor: 10.787

Review 3.  The pathogenesis of atherosclerosis--an update.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1986-02-20       Impact factor: 91.245

4.  Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro.

Authors:  M Campbell-Boswell; A L Robertson
Journal:  Exp Mol Pathol       Date:  1981-10       Impact factor: 3.362

Review 5.  Clinical pharmacology of the ACE inhibitors.

Authors:  F Fyhrquist
Journal:  Drugs       Date:  1986       Impact factor: 9.546

6.  Static mechanical properties of the developing and mature rat aorta.

Authors:  C L Berry; S E Greenwald; J F Rivett
Journal:  Cardiovasc Res       Date:  1975-09       Impact factor: 10.787

7.  Differential effects of antihypertensive drug therapy on vascular smooth muscle cell hypertrophy, hyperploidy, and hyperplasia in the spontaneously hypertensive rat.

Authors:  G K Owens
Journal:  Circ Res       Date:  1985-04       Impact factor: 17.367

8.  Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats.

Authors:  G K Owens
Journal:  Hypertension       Date:  1987-02       Impact factor: 10.190

9.  Developmentally regulated production of platelet-derived growth factor-like molecules.

Authors:  R A Seifert; S M Schwartz; D F Bowen-Pope
Journal:  Nature       Date:  1984 Oct 18-24       Impact factor: 49.962

10.  Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells.

Authors:  A A Geisterfer; M J Peach; G K Owens
Journal:  Circ Res       Date:  1988-04       Impact factor: 17.367

View more
  2 in total

Review 1.  Therapeutic effect on left ventricular hypertrophy by different antihypertensive drugs.

Authors:  W Motz; B E Strauer
Journal:  Clin Investig       Date:  1992

Review 2.  Perindopril. A review of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  P A Todd; A Fitton
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.